Summary
4MRNA Chart
Moderna, Inc. (MRNA) Presents at Barclays Speaking the Science Call Series Transcript
Moderna, Inc. (NASDAQ:MRNA ) Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ET Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Rose Loughlin - Executive Vice President of Research Conference Call Participants Huidong Wang - Barclays Bank PLC, Research Division Huidong Wang My name is Gena Wang. I'm SMID Cap biotech analyst at the Barclays.
Here's Why Moderna (MRNA) Fell More Than Broader Market
Moderna (MRNA) closed the most recent trading day at $26.68, moving 2.45% from the previous trading session.
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease. This approval expands the previous indication of mRESVIA, which was approved in May 2024 for adults aged 60 years and older.
MODERNA Dividends
MODERNA Earnings
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | 0.03 EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 1 Aug 2024 Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | 0.03 EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 1 Aug 2024 Date | | - Cons. EPS | - EPS |
MODERNA (4MRNA) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has MODERNA ever had a stock split?
MODERNA Profile
| Biotechnology Industry | Healthcare Sector | Mr. Stephane Bancel CEO | XMIL Exchange | US60770K1079 ISIN |
| US Country | 5,800 Employees | - Last Dividend | - Last Split | 7 Dec 2018 IPO Date |
Overview
Moderna, Inc., is a pioneering biotechnology firm founded in 2010, with its headquarters located in Cambridge, Massachusetts. Initially known as Moderna Therapeutics, Inc., the company rebranded to Moderna, Inc. in August 2018. It specializes in leveraging messenger RNA (mRNA) technology to develop, discover, and commercialize therapeutics and vaccines for a wide array of diseases. These diseases range from infectious diseases, immuno-oncology, rare diseases, to autoimmune and cardiovascular diseases. Moderna's operations span across the United States, Europe, and globally. The company has established strategic alliances and collaborations with notable entities in the biotech and pharmaceutical industry, including AstraZeneca, Merck & Co., Inc, Vertex Pharmaceuticals, Chiesi Farmaceutici S.p.A., and The Bill & Melinda Gates Foundation, among others.
Products and Services
- Respiratory Vaccines
Moderna's respiratory portfolio includes vaccines against COVID-19, influenza, and respiratory syncytial virus. The company utilizes its mRNA technology to develop vaccines like Spikevax, as well as its hMPV/PIV3 vaccine candidates, targeting multiple respiratory pathogens.
- Latent Vaccines
The latent vaccines developed by Moderna target a variety of viruses such as the cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella zoster virus, and the human immunodeficiency virus. These vaccines aim to provide immunity against viruses that remain dormant in the body and can cause disease upon reactivation.
- Public Health Vaccines
Moderna's public health vaccines include projects against diseases like Zika, Nipah, and Mpox. These vaccines are part of Moderna's commitment to addressing emerging public health threats and pandemics with swift vaccine development.
- Infectious Diseases Vaccines
Vaccines against Lyme disease and norovirus fall under this category. Moderna leverages its mRNA platform to create vaccines designed to protect against widespread and challenging infectious diseases.
- Systemic Secreted and Cell Surface Therapeutics
This innovative category includes therapies that are administered systemically to target secreted and cell surface proteins, leveraging mRNA technology for treating various conditions beyond infectious diseases, including potential treatments for autoimmune and cardiovascular diseases.
- Cancer Vaccines
Moderna's oncology portfolio includes personalized cancer vaccines, KRAS vaccines, and checkpoint vaccines. These products represent an extension of mRNA technology into the field of immuno-oncology, targeting the immune system to fight cancer.
- Intratumoral Immuno-Oncology Products
These are innovative treatments administered directly into tumors to elicit a more potent and localized immune response against cancer. They form part of Moderna's broader strategy to harness the body's immune system in combating cancer.
- Rare Disease Intracellular Therapeutics
Moderna is developing therapies for rare diseases by targeting intracellular mechanisms. These therapeutics are designed to address genetic disorders and diseases with limited treatment options.
- Inhaled Pulmonary Therapeutics
The company is also exploring the potential of inhaled therapies for diseases affecting the lungs, utilizing its mRNA technology to create novel treatments for pulmonary conditions.
Contact Information
